Investment analysts at UBS Group assumed coverage on shares of LHC Group (NASDAQ:LHCG) in a report issued on Thursday, The Fly reports. The brokerage set a “buy” rating on the health services provider’s stock.
A number of other analysts have also recently issued reports on the stock. Bank of America set a $119.00 price objective on shares of LHC Group and gave the stock a “buy” rating in a research note on Tuesday, September 18th. Zacks Investment Research cut shares of LHC Group from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Cantor Fitzgerald assumed coverage on shares of LHC Group in a research note on Wednesday, September 12th. They issued an “overweight” rating and a $117.00 price objective for the company. BidaskClub raised shares of LHC Group from a “hold” rating to a “buy” rating in a research note on Thursday, August 16th. Finally, SunTrust Banks raised their target price on shares of LHC Group to $115.00 and gave the company a “buy” rating in a research note on Thursday, September 13th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $105.64.
Shares of NASDAQ LHCG traded up $3.07 during midday trading on Thursday, reaching $96.19. The stock had a trading volume of 285,221 shares, compared to its average volume of 288,029. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.61 and a quick ratio of 1.61. The stock has a market cap of $3.00 billion, a PE ratio of 39.75, a price-to-earnings-growth ratio of 1.60 and a beta of 0.80. LHC Group has a 12-month low of $58.65 and a 12-month high of $103.79.
In other LHC Group news, CEO Keith G. Myers sold 75,000 shares of LHC Group stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $95.10, for a total value of $7,132,500.00. Following the completion of the transaction, the chief executive officer now directly owns 200,765 shares of the company’s stock, valued at approximately $19,092,751.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Donald Dwayne Stelly sold 2,756 shares of LHC Group stock in a transaction on Friday, September 7th. The stock was sold at an average price of $99.32, for a total transaction of $273,725.92. Following the completion of the transaction, the chief operating officer now directly owns 104,512 shares of the company’s stock, valued at $10,380,131.84. The disclosure for this sale can be found here. Insiders have sold 79,677 shares of company stock valued at $7,587,030 over the last ninety days. 6.80% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of LHCG. BlackRock Inc. grew its stake in shares of LHC Group by 76.9% in the 2nd quarter. BlackRock Inc. now owns 4,619,436 shares of the health services provider’s stock worth $395,377,000 after buying an additional 2,008,433 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of LHC Group by 74.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,133,200 shares of the health services provider’s stock worth $182,581,000 after buying an additional 911,625 shares in the last quarter. FMR LLC grew its stake in shares of LHC Group by 297.8% in the 2nd quarter. FMR LLC now owns 1,151,406 shares of the health services provider’s stock worth $98,548,000 after buying an additional 861,952 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of LHC Group by 162.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 711,508 shares of the health services provider’s stock worth $60,897,000 after buying an additional 439,947 shares in the last quarter. Finally, American Century Companies Inc. purchased a new position in shares of LHC Group in the 3rd quarter worth $35,964,000. 88.22% of the stock is owned by institutional investors and hedge funds.
LHC Group Company Profile
LHC Group, Inc, a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.
Featured Article: What is the 52-week high/low?
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.